1035.0000 1.20 (0.12%)
NSE Sep 18, 2025 09:07 AM
Volume: 293
 

1035.00
0.12%
Angel Broking
For 4QFY2017, Cadila Healthcare posted lower than expected results. The sales came in at `2,418cr (v/s. `2,800cr expected) v/s. `2,270cr in 4QFY2016, a yoy growth of 6.5%. On the operating front, the EBITDA margin came in at 16.7% v/s. 21.4% (v/s. 15.7% expected) in 4QFY2016. The GPMs came in at 61.6% (v/s. 65.7% in 4QFY2016), which resu..
Zydus Lifesciences Ltd. is trading above all available SMAs
More from Zydus Lifesciences Ltd.
All Rapid Results
Recommended